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Abstract
While conventional LDL-C, HDL-C, and triglyceride measurements reflect aggregate properties of plasma lipoprotein
fractions, NMR-based measurements more accurately reflect lipoprotein particle concentrations according to class (LDL,
HDL, and VLDL) and particle size (small, medium, and large). The concentrations of these lipoprotein sub-fractions may be
related to risk of cardiovascular disease and related metabolic disorders. We performed a genome-wide association study of
17 lipoprotein measures determined by NMR together with LDL-C, HDL-C, triglycerides, ApoA1, and ApoB in 17,296 women
from the Women’s Genome Health Study (WGHS). Among 36 loci with genome-wide significance (P,561028) in primary
and secondary analysis, ten (PCCB/STAG1 (3q22.3), GMPR/MYLIP (6p22.3), BTNL2 (6p21.32), KLF14 (7q32.2), 8p23.1, JMJD1C
(10q21.3), SBF2 (11p15.4), 12q23.2, CCDC92/DNAH10/ZNF664 (12q24.31.B), and WIPI1 (17q24.2)) have not been reported in
prior genome-wide association studies for plasma lipid concentration. Associations with mean lipoprotein particle size but
not cholesterol content were found for LDL at four loci (7q11.23, LPL (8p21.3), 12q24.31.B, and LIPG (18q21.1)) and for HDL
at one locus (GCKR (2p23.3)). In addition, genetic determinants of total IDL and total VLDL concentration were found at
many loci, most strongly at LIPC (15q22.1) and APOC-APOE complex (19q13.32), respectively. Associations at seven more loci
previously known for effects on conventional plasma lipid measures reveal additional genetic influences on lipoprotein
profiles and bring the total number of loci to 43. Thus, genome-wide associations identified novel loci involved with
lipoprotein metabolism—including loci that affect the NMR-based measures of concentration or size of LDL, HDL, and VLDL
particles—all characteristics of lipoprotein profiles that may impact disease risk but are not available by conventional assay.
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Introduction
Standard measures of plasma lipoprotein concentration do not
reveal heterogeneity in the size of lipoprotein particles or their
content of cholesterol and triglycerides. Yet recognizing this
heterogeneity may be essential for understanding qualitative
differences in lipid metabolism among individuals. Some reports
identify a pattern in the size distribution of lipoprotein sub-
fractions as intimately connected with coronary heart disease [1,2].
Related findings identify a link between lipoprotein profile and
metabolic syndrome, and by inference to diabetes [3]. While these
observations remain controversial for prognostic use [4], they
point to alterations in lipoprotein metabolism in disease.
The variation in particle size and lipid content can be quantified
accurately by NMR-based methods that determine lipoprotein
particle concentration according to lipid class and particle size.
Thus, NMR methods can measure concentration of large and
small low density lipoprotein (LDL) particles as well as
concentration of the related intermediate density lipoprotein
(IDL) particles, and similarly concentration of small, medium,
and large high density lipoprotein (HDL) or very low density
lipoprotein (VLDL) particles. HDL and LDL particle concentra-
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tion can also be estimated by chemical measures of apolipoprotein
A1 (ApoA1) and apolipoprotein B (ApoB) protein concentration,
respectively, but neither these assays nor other standard clinical
assays provide information about particle size distribution, and
consequently the apportionment of cholesterol and triglycerides to
different sized particles. The greater precision in characterizing
lipoprotein profiles using NMR-based techniques provides an
opportunity for correspondingly greater detail in understanding
lipid metabolism, for example by genome-wide genetic analysis, as
has been done recently for plasma concentration LDL-C, HDL-C,
triglycerides, ApoA1, and ApoB [5–13].
Results
Genome-wide association analysis of 22 NMR-based and
conventional lipoprotein fractions
Among 17,296 WGHS participants with confirmed European
ancestry (Table 1), we performed genome-wide association
analysis assuming an additive genetic model for 22 plasma
lipoprotein measures determined either by NMR methods or by
standard clinical assay. On the basis of genome-wide significance
(P,561028), genetic variation at total of 31 loci was associated
with at least one of the lipoprotein fractions (Table 2). Thirty of
these 31 loci derive from analysis in the whole sample, while the
remaining locus was identified with genome-wide significance in a
subset of 12,489 (72%) strictly fasting participants, for whom there
were small but significant differences in lipoprotein profiles
compared with non-fasting participants (Table 1). Nearly all of
the associations with genome-wide significance level in the fasting
subsample also had genome-wide significance in the larger, better
powered whole sample. One exception was the genome-wide
significant association with ApoA1 at ABCA1 (9q31.1), a locus that
was identified in the whole sample on the basis of genome-wide
significant associations with HDL-C and medium HDL particles
but not for ApoA1. The other was an association with mean
VLDL size at 8p23.1, a locus that appears only in analysis in the
fasting sub-sample (Table 2). These additional associations remain
strongly suggestive in the whole sample (P,1.661025) even
though they do not reach genome-wide significance. Statistics for
the most significant genome-wide associations with P,561028 at
each of the candidate loci are shown in the Table S1.
Seven of the 31 unique loci reveal novel genome-wide
significant associations with the plasma lipoprotein fractions (see
bold font type, Table 2). The associations at 3q22.3 (PCCB/
STAG1), 6p21.32 (BTNL2), 7q32.2 (KLF14), 12q24.31.B (CCDC9/
DNAH10/ZNF664) and 17q24.2 (WIPI1) are all near genes (Figure
S1), while genome-wide significant associations at the remaining
two novel loci, 8p23.1 and 12q23.2 are remote (i.e. .150kb) from
known genic regions. Among the standard clinical measures LDL-
C, HDL-C, and triglycerides only, novel genome-wide loci were
found at KLF14 (7q32.2) and CCDC9/DNAH10/ZNF664
Table 1. WGHS population.
whole sample fasting subsample
N with genotype 17,296 12,489
Clinical characteristics*
age (yrs)‘ 53 (49–59) 53 (49–59)
BMI (kg/m2) 25 (22–28) 25 (22–28)
smoking (%) 2055 (12) 1508 (12)
+HRT use (%) 7537 (44) 5460 (44)
diabetes (%) 0 (0) 0 (0)
hypertension (%)‘ 3943 (23) 2950 (24)
#lipid lowering trt. (%) 0 (0) 0 (0)
Lipoprotein fractions*
LDL large (nmol/l)‘ 540 (404–680) 547 (407–685)
LDL small (nmol/l) 650 (399–1008) 646 (393–1010)
LDL mean size (nm) 21 (21–22) 21 (21–22)
IDL total (nmol/l)‘ 32 (11–67) 34 (12–71)
LDL total (nmol/l) 1272 (1029–1591) 1274 (1032–1594)
LDL-C assay (mg/dl)‘ 121 (100–145) 123 (102–146)
ApoB assay (mg/dl)‘ 99 (83–120) 100 (84–121)
HDL total (mmol/l)‘ 35 (31–39) 35 (31–40)
HDL large (mmol/l)‘ 8 (5–10) 8 (5–10)
HDL medium (mmol/l) 3 (0.8–6.0) 3 (0.7–5.9)
HDL small (mmol/l)‘ 24 (20–27) 24 (20–27)
HDL mean size (nm)‘ 9 (9–9) 9 (9–9)
HDL-C by NMR (mg/dl) 53 (44–64) 53 (44–64)
HDL-C assay (mg/dl) 52 (44–63) 52 (44–63)
ApoA1 assay (mg/dl) 150 (133–169) 150 (133–169)
VLDL total (nmol/l) 69 (50–90) 68 (49–91)
VLDL large (nmol/l)‘ 1 (0.4–3.7) 1 (0.3–3.5)
VLDL medium (nmol/l)‘ 21 (11–32) 20 (11–32)
VLDL small (nmol/l)‘ 45 (33–58) 45 (33–58)
VLDL mean size (nm)‘ 47 (42–52) 46 (42–51)
TG by NMR (mg/dl)‘ 109 (82–146) 107 (81–144)
TG assay (mg/dl)‘ 117 (83–172) 113 (81–166)
*Clinical characteristics are given as number (fraction) or median (interquartile
range). Lipoprotein measures are given as median (interquartile range).
‘p,0.001 for comparison of non-fasting (N = 4,807) fasting (N = 12,489)
samples.
+HRT is abbreviation for hormone replacement therapy.
#lipid lowering treatment.
doi:10.1371/journal.pgen.1000730.t001
Author Summary
Genome-wide association studies (GWAS) of plasma
lipoprotein fractions hold great promise for understanding
lipid metabolism and its central role in cardiovascular
disease and related disorders. Conventional assays for
lipoprotein status determine total cholesterol content of
low- or high-density lipoprotein particles (LDL-C or HDL-C,
respectively) or total plasma triglyceride content (as an
estimate of very-low density lipoprotein particle concen-
tration [VLDL]). All three measures have been targets for
recent GWAS. However, a more precise target for GWAS of
lipoprotein metabolism would be the concentration of the
individual lipoprotein particles according to class (LDL,
HDL, VLDL) and size (small, medium, and large), all of
which can be measured by NMR-based methods. In a
population of 17,296 women of European ancestry from
the Women’s Genome Health Study, we have performed a
GWAS for 22 lipoprotein measures derived from NMR-
based and conventional assays. We find 43 genetic loci
involved in lipoprotein metabolism, including 10 novel
loci. The results offer a clearer picture of common genetic
influences on lipoprotein metabolism than available
previously, including genetic effects on the distribution
of LDL, HDL, and VLDL particle size, as well as on IDL and
VLDL particle concentration, neither of which can be
assessed by conventional measures.
Large-Scale GWAS of 22 Lipoprotein Measures
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(12q24.31.B), both for triglycerides. The association at the novel
locus 8p23.1 (which differentiated the fasting sample from the
whole sample on the basis of mean VLDL particle size) is over
1.8 Mb from a recently described association at 8p23.1 between
SNP rs7819412 and triglycerides [6].
The remaining 24 unique loci suggested genes recognized for a
diversity of roles in lipid metabolism, broadly defined (Figure S1).
Thus, SNPs with genome-wide significance, were confirmed in or
near PCSK9 (at 1p32.3), APOA2 (1q23.3), APOB (2p24.1), ABCG5/
8 (2p21), HMGCR (5q13.3), LPL (8p21.3), APOA1-A5 (11q23.3),
ABCA1 (9q31.1), FADS1-3 (11q12.2), LIPC (15q22.1), CETP
(16q13), LIPG (18q21.1), LDLR (19p13.2), the APOC-APOE
complex (19q13.32), and PLTP (20q13.12). Similarly, association
at 9q34.2 implicating the ABO gene recapitulates and extends the
known association between blood group antigen and total
cholesterol [14,15]. Less well characterized genic regions, which
nonetheless have been validated recently for roles in lipid
metabolism, were confirmed for ANGPTL3 (1p31.3), CELSR2/
MYBPHL/PSRC1/SORT1 (1p13.3), GCKR (2p23.3), MLXIPL
(7q11.23), and TRIB1 (8q24.13), HNF1A (12q24.31.A), and
HNF4A (20q13.12). The association at COBLL1/GRB14 (2q24.3)
with HDL-C was recently described elsewhere in this same cohort
Table 2. Loci and candidate genes with genome-wide significant associations (p,561028) for 22 lipoprotein measures.
locus whole sample fasting subsample candidate gene(s)
1p32.3 APOB, LDL-C, LDL:T, LDL:L, TG:N, VLDL:T, VLDL:S APOB, LDL-C, LDL:T, LDL:L, VLDL:T, VLDL:S PCSK9
1p31.3 TG:N, VLDL:T, VLDL:M, VLDL:S TG:N, VLDL:T, VLDL:M, VLDL:S ANGPTL3
1p13.3 APOB, LDL-C, LDL:T, LDL:L, LDL:S, VLDL:T, VLDL:S APOB, LDL-C, LDL:T, LDL:S, VLDL:S CELSR2, PSRC1, SARS, SORT1
1q23.3 HDL:M HDL:M APOA2
2p24.1 APOB, LDL-C, LDL:T, LDL:L, LDL:Z, TG:N, TG, VLDL:T, VLDL:M,
VLDL:S, VLDL:Z
APOB, LDL-C, LDL:T, LDL:L, TG:N, TG, VLDL:T, VLDL:M,
VLDL:S, VLDL:Z
APOB
2p23.3 APOA1, APOB, HDL:T, HDL:S, HDL:Z, IDL:T, LDL:T, LDL:S, LDL:Z,
TG:N, TG, VLDL:L, VLDL:T, VLDL:M, VLDL:Z
APOA1, APOB, HDL:T, HDL:S, HDL:Z, IDL:T, LDL:T, LDL:S,
LDL:Z, TG:N, TG, VLDL:L, VLDL:T, VLDL:M, VLDL:Z
GCKR
2p21 APOB, LDL-C LDL-C ABCG5/8
2q24.3 HDL-C - COBLL1, GRB14
3q22.3 HDL:S - PCCB, STAG1
5q13.3 LDL-C, LDL:L LDL-C, LDL:L HMGCR
6p21.32 TG:N, VLDL:L TG:N, VLDL:L BTNL2,HLA-DRA, HLA-DRB5
7q11.23 HDL:S, LDL:L, LDL:S, LDL:Z, TG:N, TG, VLDL:L, VLDL:T, VLDL:M TG:N, TG, VLDL:M MLXIPL
7q32.2 HDL:Z, LDL:T, LDL:S, TG - COPG2, KLF14, TSGA13
8p23.1 - VLDL:Z intergenic PPP1R3B
8p21.3 APOA1, HDL-C, HDL:L, HDL:Z, LDL:L, LDL:S, LDL:Z, HDL:N, TG:N,
TG, VLDL:L, VLDL:T, VLDL:M, VLDL:S
APOA1, HDL-C, HDL:L, HDL:Z, LDL:L, LDL:S, LDL:Z, HDL:N,
TG:N, TG, VLDL:L, VLDL:T, VLDL:M, VLDL:S
LPL
8q24.13 APOB, LDL:T, LDL:S, LDL:Z, TG:N, TG APOB, LDL:T, LDL:S TRIB1
9q31.1 HDL-C, HDL:M APOA1, HDL-C ABCA1
9q34.2 LDL-C, LDL:L, VLDL:S, VLDL:Z LDL-C, VLDL:S ABO
11q12.2 HDL:L, HDL:M, HDL:Z, LDL:L HDL:L, HDL:M, HDL:Z, LDL:L FADS1-3
11q23.3 APOA1, APOB, HDL-C, HDL:T, HDL:S, LDL:T, LDL:S, LDL:Z, HDL:N,
TG:N, TG, VLDL:L, VLDL:T, VLDL:M, VLDL:S
APOA1, APOB, HDL-C, HDL:T, HDL:S, LDL:T, LDL:S, LDL:Z,
HDL:N, TG:N, TG, VLDL:L, VLDL:T, VLDL:M, VLDL:S
APOA1-A5
12q23.2 HDL:T, HDL:N - intergenic ASCL1, PAH
12q24.31.A LDL-C - HNF1A/TCF1
12q24.31.B HDL:L, HDL:Z, LDL:T, LDL:S, LDL:Z, TG HDL:L CCDC92, DNAH10, ZNF664
15q22.1 APOA1, HDL-C, HDL:L, HDL:M, HDL:S, HDL:Z, IDL:T, LDL:L, LDL:S,
LDL:Z, HDL:N
APOA1, HDL-C, HDL:L, HDL:S, HDL:Z, IDL:T, LDL:L, LDL:S,
LDL:Z, HDL:N
LIPC
16q13 APOA1, HDL-C, HDL:T, HDL:L, HDL:Z, IDL:T, LDL:T, LDL:L, LDL:S,
LDL:Z, HDL:N, TG, VLDL:T, VLDL:S
APOA1, HDL-C, HDL:T, HDL:L, HDL:Z, IDL:T, LDL:T, LDL:L,
LDL:S, LDL:Z, HDL:N, VLDL:T, VLDL:S
CETP
17q24.2 HDL:M - PRKAR1A, WIPI1
18q21.1 APOA1, HDL-C, HDL:L, HDL:Z, LDL:L, LDL:Z, HDL:N APOA1, HDL-C, HDL:L, HDL:Z, LDL:L, LDL:Z, HDL:N LIPG
19p13.2 APOB, LDL-C, LDL:T, LDL:L, VLDL:S APOB, LDL-C, LDL:T, LDL:L, VLDL:S LDLR
19q13.32 APOA1, APOB, HDL-C, HDL:M, LDL-C, LDL:T, LDL:L, LDL:S, LDL:Z,
HDL:N, TG:N, TG, VLDL:L, VLDL:T, VLDL:M, VLDL:S
APOA1, APOB, HDL-C, HDL:M, LDL-C, LDL:T, LDL:L, LDL:S,
HDL:N, TG:N, TG, VLDL:L, VLDL:T, VLDL:S
APOC1,2-APOE
20q13.12.A APOA1 - HNF4A
20q13.12.B HDL-C, HDL:T, HDL:L, HDL:S, HDL:Z, LDL:T, LDL:L, LDL:S, LDL:Z, TG HDL-C, HDL:T, HDL:L, HDL:S, HDL:Z, LDL:L, LDL:S, LDL:Z, TG PLTP
LDL = low density lipoprotein, IDL = intermediate density lipoprotein, HDL =high density lipoprotein, VLDL = very low density lipoprotein, APOB= apolipoprotein B,
APOA1 = apolipoprotein A1.
X:L = large particles, X:M =medium particles, X:S = small particles, X:Z =mean particle size, X:T total particles, X:N = assay by NMR, X-C = cholesterol.
Bold type face indicates novel loci.
doi:10.1371/journal.pgen.1000730.t002
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and validated by replication [16]. The previous study found much
stronger association in women than men, suggesting a potential
interaction with gender. At this locus, the gene GRB14 is thought
to inhibit receptors in the insulin receptor class [17,18]. The
current analysis extends associations at this locus to concentrations
of LDL, HDL, and VLDL particles according to size (Table S1).
Consistent with a high degree of correlation among the
lipoprotein measures (Table S2), the rank order by p-value among
the highly significant SNPs was similar for each measure with at
least one genome-wide significant association (Figure S1). A
notable exception was the APOB gene (2p24.1), where the ordering
of the p-values, conditional analysis, and patterns of linkage
disequlibrium (LD) among the top SNPs (Table S1) revealed three
classes of associations. One class included VLDL-related fractions,
triglycerides, and mean LDL size for which either rs673548 or
rs676210 (LD r2 = 1.0) had the strongest association; a second class
included ApoB, large LDL particles, and total LDL particles for
which either rs1713222 or rs506585 (LD r2 = 0.5) had the
strongest association; and a final class including only LDL-C for
which rs137117 was most strongly associated (Figure 1A). Between
SNPs in different classes, maximum LD ranged from r2= 0.04–
0.11. Similarly, at APOA5-APOA1 (11q23.3), p-values revealed two
classes of associations seemingly segregating between effects nearer
the APOA5 gene involving triglycerides and effects nearer the
APOA1 gene involving HDL related lipoprotein fractions
(Figure 1B).
Large, well-characterized cohorts with NMR-based measure-
ment of lipoprotein fractions are scant, but sub-samples of about
2700 participants in the Framingham Heart Study Offspring cohort
(FHS) [19] and about 2000 total CHD cases and controls from
PROCARDIS [20] had both the NMR-based lipoprotein measures
and genome-wide genetic data already determined. Among all
candidate loci, concordance of direction of effects was observed
respectively at 124 out of 146 (84%) [84% in fasting sub-sample]
and 125 out of 133 (94%) [99% in fasting sub-sample] of the
candidate associations for which there was genotype information in
FHS and PROCARDIS (Table S3 [whole WGHS sample
candidates], Table S4 [fasting WGHS subsample candidates]).
For each of the previously known loci except ABCA1 (9q31), at least
one of the candidate associations was nominally significant (P,0.05,
two-sided) in at least one of the replication cohorts or in analysis
combining p-values from the two replication cohorts when effect
estimates (beta coefficients) indicated trends in lipoprotein measure
consistent with the effects observed in the WGHS. Among the 7
novel loci from the primary analysis only, where the effect estimates
for theWGHSwere generally smaller and power for replication was
less, concordance of the direction of effects remained high for the
PROCARDIS sample [86% (25/29)], although only modest for the
FHS sample [58% (22/38)], but these associations were not
significant (two-sided P.0.05; Table S3). However, a recent
genome-wide meta-analysis of LDL-C, HDL-C, and triglycerides
found significant, but not genome-wide significant, associations
among these fractions with candidate SNPs from the WGHS at
PCCB/STAG1 (3q22.3), BTNL2 (6p21.32), KLF14 (7q32.2), and
8p23.1 [10], although the significant SNP associations at PCCB/
STAG1 (3q22.3) and BTNL2 (6p21.32) were not fully concordant
between the two studies (Table 3). Independent evidence for
functional consequence of the candidate SNP (rs10778213) at
12q23.2 is its genome-wide significant association in a smaller
sample from the WGHS with plasma C-reactive protein (CRP), a
biomarker of inflammation that is slightly correlated if at all with the
two HDL measures associated at this locus (total HDL particle
concentration [HDL:T], Spearman r= 0.22; HDL cholesterol
estimated by the NMR [HDL:N], Spearman r=20.04) [21]. With
the larger sample of WGHS genotype information in the current
study, the association with plasma CRP is more significant
(P,5610215). Finally, the associations at CCDC92/DNAH10/
ZNF664 [12q24.31.B] and WIPI1 (17q24.2) were not confirmed
either in the meta-analysis shown in Table 3 or in a second genome-
wide meta-analysis of LDL-C, HDL-C, and triglycerides that also
evaluated gender stratified association [11] (data not shown).
Nevertheless, ongoing genotyping in the WGHS of an additional
4639 samples (3305 with fasting status) completed subsequent to the
main analysis provided significant support for these last two loci on
the basis of internal replication, as well as significant or borderline
significant support for four others, confirming directions of effects
for all novel candidate associations, and leading to smaller p-values
in analysis combining the main WGHS sample with the additional
samples for all but three entries in Table 3 and at least one
lipoprotein measure for each locus (compare to Table S1).
Magnitudes of genetic effects
To assess the contribution of common genetic variation at each
of the candidate loci to each of the adjusted lipoprotein fractions,
we constructed regression models by stepwise selection of SNPs in
the vicinity of the primary genome-wide significant associations.
Most of these models explain less than 1% of the variation in the
adjusted lipoprotein fractions (Figure 2, Table S5, and Table S6).
The top three effects, all at APOC-APOE complex (19q13.32),
explain 8.9%, 8.4%, and 7.1% of the variance in ApoB particle
concentration, the related total LDL particle concentration, and
LDL-C, respectively. Fasting status had an influence on retention
of SNPs in the model selection procedure, but only for loci with
modest effects (Compare Table S5 and Table S6). There were no
genetic contributions remaining from the model selection
procedure for any of LDL-C, HDL-C, triglycerides, ApoA1, or
ApoB concentration at APOA2 (1q23.3) in the whole sample and at
WIPI1 (17q24.2) in the fasting subsample, suggesting that these
loci would not have been identified for genome-wide association
with the five conventional lipoprotein fractions even in a much
larger sample with the genome-wide SNP genotyping panel used
in this study. Clustering loci on the basis of the profile of associated
lipoprotein fractions suggests sub-groups of loci with related
patterns of effects (Figure S2, Figure S3), perhaps suggesting
distinct but possibly overlapping biological pathways for lipopro-
tein metabolism. For example, HNF1A, LDLR, ABCG5/8, PCSK9,
and CELSR2/PSRC1/SARS/SORT1 largely share associations with
IDL, small VLDL, total VLDL large LDL, LDL-C, total LDL,
and ApoB.
The total genetic effects for each lipoprotein determined by
summing over the effects at all loci ranged from 2.1% for mean
VLDL size to 17.2% for ApoB (Table 4). The effects were not
substantially different when the entire model selection procedure
was performed in the fasting subsample (Table 4), and only slightly
smaller in general among the unadjusted lipoprotein fractions
(Table S7). Notably, the common genetic variation in this study at
the genome-wide loci had a greater total effect on mean particle
size than on standard clinical cholesterol measures for HDL but
not for LDL or VLDL (Table 4).
Secondary genome-wide analysis
To examine the possibility that other loci might include SNPs with
genome-wide significant association conditional on effects at the
primary loci, we adjusted the primary lipoprotein fraction
measurements (which were already adjusted for clinical covariates)
for SNPs retained by the model selection procedure at the candidate
loci, and repeated the genome-wide association testing. Quantile-
quantile analysis confirmed that all of the excess of extremely small
Large-Scale GWAS of 22 Lipoprotein Measures
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p-values in the original analysis could be explained by the variation
at the candidate loci (not shown). Similarly, genotype-based
statistical models (as opposed to the allele-based additive models
used in the primary analysis) did not reveal other loci with genetic
influences at the genome-wide significance level in the whole sample.
While we adjusted the lipoprotein measures with a full set of
clinical characteristics to reduce variance and enhance power in the
primary analysis, it remained possible that relevant SNPs would be
overlooked if they acted through effects on the adjustment
covariates. Similarly, subtle effects on the association estimates
Figure 1. Loci with distinct classes of SNP associations among lipoprotein fractions with genome-wide significance. (A) APOB locus
(2p24.1), (B) APOA1-A5 locus (11q23.3). Recombination rates are from [41].
doi:10.1371/journal.pgen.1000730.g001
Large-Scale GWAS of 22 Lipoprotein Measures
PLoS Genetics | www.plosgenetics.org 5 November 2009 | Volume 5 | Issue 11 | e1000730
T
a
b
le
3
.
R
e
p
lic
at
io
n
o
f
as
so
ci
at
io
n
s
w
it
h
LD
L-
C
,
H
D
L-
C
,
an
d
tr
ig
ly
ce
ri
d
e
s
at
n
o
ve
l
lo
ci
.
W
G
H
S
M
e
ta
-a
n
a
ly
si
sa
L
o
cu
s
g
e
n
e
(s
)
sa
m
p
le
le
a
d
S
N
P
b
le
a
d
fr
a
ct
io
n
(s
)b
in
te
rn
a
l
re
p
li
ca
ti
o
n
p
-v
a
lu
e
c
E
x
te
n
d
e
sa
m
p
le
p
-v
a
lu
e
c
L
D
L
-C
d
H
D
L
-C
d
T
G
d
N
L
D
L
-C
d
H
D
L
-C
d
T
G
d
3
q
2
2
.3
P
C
C
B
ST
A
G
1
al
l
rs
3
8
5
6
6
3
7
H
D
L:
S
(+
)
0
.0
1
8
1
.1
6
1
0
2
9
n
.s
.
1
.1
6
1
0
2
2
(+
)
n
.s
.
1
8
5
1
6
0
.1
4
(+
)
0
.2
0
(2
)
3
.0
6
1
0
2
5
(+
)
6
p
2
1
.3
2
B
TN
L2
al
l
rs
2
0
7
6
5
3
0
V
LD
L:
L
(+
)
0
.3
4
1
.6
6
1
0
2
7
n
.s
.
n
.s
.
5
.4
6
1
0
2
7
(+
)
1
9
5
8
4
0
.9
4
(2
)
0
.0
3
4
(2
)
0
.3
3
(2
)
T
G
:N
(+
)
0
.0
6
5
1
.3
6
1
0
2
9
fa
st
in
g
rs
3
1
2
9
8
8
2
V
LD
L:
L
(2
)
0
.0
5
7
1
.8
6
1
0
2
8
n
.s
.
5
.9
6
1
0
2
4
(+
)
2
.1
6
1
0
2
7
(2
)
1
9
6
4
8
0
.4
7
(2
)
7
.0
6
1
0
2
3
(+
)
0
.3
5
(2
)
T
G
:N
(2
)
0
.1
4
1
.8
6
1
0
2
8
7
q
3
2
.2
K
LF
14
al
l
rs
4
7
3
1
7
0
2
LD
L:
S
(2
)
0
.0
0
0
1
9
5
.3
6
1
0
2
9
4
.1
6
1
0
2
3
(2
)
4
.9
6
1
0
2
7
(+
)
2
.2
6
1
0
2
9
(2
)
1
9
6
4
8
0
.5
6
(2
)
8
.8
6
1
0
2
7
(+
)
5
.9
6
1
0
2
3
(2
)
LD
L:
T
(2
)
0
.0
0
2
8
5
.4
6
1
0
2
1
1
H
D
L:
Z
(+
)
0
.0
0
6
5
1
.0
6
1
0
2
1
0
T
G
(2
)
0
.0
0
2
6
2
.7
6
1
0
2
1
1
8
p
2
3
.1
In
te
rg
en
ic
P
P
P
1R
3B
fa
st
in
g
rs
9
8
3
3
0
9
V
LD
L:
Z
(+
)
0
.1
4
3
.8
6
1
0
2
9
3
.7
6
1
0
2
5
(2
)
5
.8
6
1
0
2
3
(2
)
1
.5
6
1
0
2
2
(+
)
1
9
6
4
8
2
.4
6
1
0
2
4
(2
)
5
.7
6
1
0
2
6
(2
)
0
.5
2
(+
)
1
2
q
2
3
.2
In
te
rg
en
ic
A
SC
L1
P
A
H
al
l
rs
1
8
1
8
7
0
2
H
D
L:
T
(2
)
0
.0
4
2
.7
6
1
0
2
1
0
n
.s
.
n
.s
.
3
.4
6
1
0
2
2
(2
)
1
9
5
3
6
0
.8
8
(+
)
0
.9
9
(2
)
0
.0
6
9
(2
)
al
l
rs
1
0
7
7
8
2
1
3
e
H
D
L:
N
(2
)
0
.0
9
6
7
.6
6
1
0
2
9
0
.0
2
1
(+
)
n
.s
.
n
.s
.
1
9
6
4
8
0
.1
2
(2
)
0
.2
2
(+
)
0
.4
7
(+
)
1
2
q
2
4
.3
1
.B
C
C
D
C
9
D
N
A
H
10
Z
N
F6
64
al
l
rs
7
3
0
7
2
7
7
H
D
L:
L
(+
)
0
.0
0
3
2
9
.0
6
1
0
2
1
3
1
.4
6
1
0
2
3
(2
)
5
.5
6
1
0
2
8
(+
)
6
.1
6
2
1
0
(2
)
1
9
6
4
8
0
.4
0
(+
)
0
.0
7
4
(2
)
0
.3
5
(+
)
H
D
L:
Z
(+
)
0
.0
0
1
3
1
.5
6
1
0
2
1
2
LD
L:
Z
(+
)
0
.0
0
7
3
5
.0
6
1
0
2
1
0
LD
L:
T
(2
)
0
.0
0
0
2
4
1
.1
6
1
0
2
1
1
LD
L:
S
(2
)
0
.0
0
0
2
9
1
.2
6
1
0
2
1
2
T
G
(2
)
0
.0
1
5
6
.7
6
1
0
2
1
1
fa
st
in
g
H
D
L:
L
(+
)
0
.0
1
0
1
.4
6
1
0
2
9
1
7
q
2
4
.2
P
R
K
A
R
1A
W
IP
I1
al
l
rs
2
9
0
9
2
0
7
H
D
L:
M
(+
)
0
.0
4
5
1
.7
6
1
0
2
9
n
.s
.
n
.s
.
2
.2
6
1
0
2
3
(+
)
1
9
6
4
8
0
.8
7
(2
)
0
.7
3
(+
)
0
.1
7
(+
)
a
M
e
ta
-a
n
al
ys
is
o
f
LD
L-
C
,
H
D
L-
C
,
an
d
T
G
am
o
n
g
1
2
Eu
ro
p
e
an
p
o
p
u
la
ti
o
n
s
[1
0
].
b
M
o
st
si
g
n
if
ic
an
t
g
e
n
o
m
e
-w
id
e
SN
P
an
d
lip
o
p
ro
te
in
fr
ac
ti
o
n
(s
)
as
so
ci
at
io
n
at
lo
cu
s
fo
r
te
st
s
am
o
n
g
th
e
2
2
lip
o
p
ro
te
in
fr
ac
ti
o
n
s.
(+
/2
)
in
d
ic
at
e
s
tr
e
n
d
o
f
fr
ac
ti
o
n
w
it
h
in
cr
e
as
in
g
co
p
ie
s
o
f
th
e
m
in
o
r
al
le
le
(s
am
e
as
si
g
n
o
f
b
e
ta
co
e
ff
ic
ie
n
t,
se
e
T
ab
le
s
2
an
d
S2
).
c
P
-v
al
u
e
(t
w
o
-s
id
e
d
)
fo
r
as
so
ci
at
io
n
in
ad
d
it
io
n
al
4
6
3
9
(a
ll)
o
r
3
3
0
5
(f
as
ti
n
g
)
sa
m
p
le
s
fr
o
m
th
e
W
G
H
S
(i
n
te
rn
al
re
p
lic
at
io
n
).
A
ll
as
so
ci
at
io
n
tr
e
n
d
s
w
e
re
co
n
si
st
e
n
t
w
it
h
d
is
co
ve
ry
sa
m
p
le
.
C
o
m
b
in
in
g
th
e
se
n
e
w
sa
m
p
le
s
w
it
h
th
e
o
ri
g
in
al
d
is
co
ve
ry
sa
m
p
le
s
le
ad
s
to
p
–
va
lu
e
s
fo
r
th
e
e
xt
e
n
d
e
d
W
G
H
S
sa
m
p
le
.
B
o
ld
fo
n
t
in
d
ic
at
e
s
p
-v
al
u
e
sm
al
le
r
th
an
in
m
ai
n
d
is
co
ve
ry
sa
m
p
le
.
d
P
-v
al
u
e
an
d
tr
e
n
d
(+
/2
)
fo
r
as
so
ci
at
io
n
o
f
in
cr
e
as
in
g
co
p
ie
s
o
f
th
e
m
in
o
r
al
le
le
w
it
h
in
d
ic
at
e
d
lip
o
p
ro
te
in
fr
ac
ti
o
n
in
e
it
h
e
r
W
G
H
S
o
r
th
e
m
e
ta
-a
n
al
ys
is
.
n
.s
.
in
W
G
H
S
an
al
ys
is
in
d
ic
at
e
s
n
o
t
si
g
n
if
ic
an
t
(P
.
0
.0
5
).
e
G
e
n
o
m
e
-w
id
e
si
g
n
if
ic
an
t
as
so
ci
at
io
n
w
it
h
p
la
sm
a
C
-r
e
ac
ti
ve
p
ro
te
in
in
th
e
W
G
H
S
[2
1
].
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
g
e
n
.1
0
0
0
7
3
0
.t
0
0
3
Large-Scale GWAS of 22 Lipoprotein Measures
PLoS Genetics | www.plosgenetics.org 6 November 2009 | Volume 5 | Issue 11 | e1000730
due to non-normality of the (possibly log-transformed) adjusted
lipoprotein measures or due sub-European population stratification
might confound hypothesis testing. To evaluate whether our
discovery procedure was robust, we performed secondary analyses
repeating the entire genome-wide discovery procedure for alterna-
tive nested subsets of clinical covariates with and without further
adjustment for population structure and quantile normalization
(Table S8). Comparing the full adjustment procedure to alternatives
using either a reduced set of clinical covariates or age only, with or
without additional adjustment for potential sub-European popula-
tion stratification and quantile normalization yielded further
genome-wide significant associations at three loci with known lipid
metabolic genes, LPA (6q25.3), LCAT (16q22.1), and APOH
(17q24.2), and two additional loci, 6p22.3 and 10q21.3. All of the
additional loci were present in the age-adjusted analysis. Associa-
tions at 6p22.3 and 10q21.3 appear to be novel and implicate,
respectively the GMPR orMYLIP genes and the JMJD1C gene. The
lead SNPs at each of these loci were significantly associated with at
least one of LDL-C, HDL-C or triglycerides in the recently
published meta-analysis (Table 5) [10]. Similarly, in internal
replication among the additional 4639 WGHS samples with
genotype available after the main analysis was complete, associa-
tions at the candidate SNPs were all significant and the trends of
effects were all consistent with effects in the discovery sample
Figure 2. Variance explained in adjusted lipoprotein measures by common variation at the candidate loci by SNPs retained in
model selection procedures. See also Figure S2 and Figure S3.
doi:10.1371/journal.pgen.1000730.g002
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(Table 5). We note that at JMJD1C (10q21.3), the candidate SNPs
have minor allele frequency near 0.5, and that available data does
not allow us to determine whether the differences in the direction of
the minor allele effect on VLDL fractions in the WGHS and
triglycerides in the previously published replication study are truly
physiological or rather that the frequency of the coded (i.e. minor)
allele from the WGHS is greater than 0.5 in the replication cohort
resulting in an opposite sign of the effect estimates.
Since lipoprotein particle size is closely related to triglyceride
content, we also performed secondary analysis examining genome-
wide significant associations after adjustment of the lipoprotein
fractions by the full set of clinical covariates and (log-transformed)
triglyceride levels (Table 5 and Table S8). This analysis identified
only one new genome-wide significant association. At 11p15.4,
rs7938647 in the intron of the SBF2 gene was associated with full-
plus-triglyceride adjusted total HDL particle concentration. Again,
internal replication provided support for this association although
there was no association (P.0.05) with LDL-C, HDL-C, or
triglycerides in the recent meta-analysis for replication.
Associations distinguishing NMR-based from
conventional lipoprotein measures
Among its unique characteristics, the NMR-based methodology
provides information about IDL and VLDL particle concentration,
both aspects of lipoprotein profiles that are difficult to measure by
conventional methods. For IDL, genetic associations were observed
at many of the candidate loci (Figure 2, Table 2, Table S1) and most
strongly at LIPC (15q22.1), where rs1532085 had an estimated
0.11 nmol/l shift in particle concentration for each copy of the minor
Table 4. Proportion (%) variance in fully adjusted lipoprotein
fractions explained by common variation at candidate loci.
lipoprotein fraction whole sample fasting subsample
LDL large 12.0 11.4
LDL small 8.9 9.4
LDL mean size 8.5 8.7
IDL total 3.5 3.5
LDL total 15.2 15.0
LDL-C assay 13.7 13.8
ApoB assay 17.2 16.8
HDL total 5.6 5.6
HDL large 13.1 12.5
HDL medium 4.6 4.4
HDL small 6.4 5.7
HDL mean size 12.2 11.7
HDL-C by NMR 10.3 9.9
HDL-C assay 9.9 9.1
ApoA1 assay 8.3 7.8
VLDL total 8.9 8.6
VLDL large 3.8 4.1
VLDL medium 6.0 6.0
VLDL small 7.6 7.4
VLDL mean size 2.1 2.5
TG by NMR 7.9 7.6
TG assay 7.7 8.1
doi:10.1371/journal.pgen.1000730.t004
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allele (p=1.5610220). For total VLDL concentration, association
with genetic variation was observed at many loci but none more
strongly than at the APOC-APOE complex where rs439401, which is
in perfect LD with rs7412 (the SNP that distinguishes APOE alleles E2
and E3), had an estimated 22.4nmol/l shift in concentration per
copy of the minor allele (p=2.1610212; Table S1).
Loci strongly affecting the relative concentration of NMR-based
estimates of small, medium, and large particle size could be identified
on the basis of genome-wide effects on mean particle size, and these
associations were of special interest when there was no accompanying
association with the corresponding cholesterol measure retained in
the model selection procedures (Table 6, Figure S4). For LDL, mean
particle size was associated with genome-wide significance at 12 loci
(Table 2), among which the model selection procedures failed to
identify any association with LDL-C at MLXIPL (7q11.23), LPL
(8p21.3), CCDC92/DNAH10/ZNF664 (12q24.31.B), and LIPG
(18q21.1). These loci implicate genes related to glucose or triglyceride
metabolism as well as unrecognized biological function at one novel
locus (CCDC92/DNAH10/ZNF664 [12q24.31.B]). The associations
with mean LDL particle size were a consequence of strong inverse
effects on large and small LDL particles (MLXIPL [7q11.23], LPL
[8p21.3], LIPG [18q21.1]) or of exclusive effects on small LDL
(CCDC92/DNAH10/ZNF664 [12q24.31.B]) [see Figure S4]. In the
fasting subsample, the associations with the NMR based measures at
LPL (8p21.3) and LIPG (18q21.1) also met genome-wide significance,
but the associations at MLXIPL (7q11.23) and CCDC92/DNAH10/
ZNF664 (12q24.31.B) did not. For HDL, 9 loci had genome-wide
significance for mean particle size (Table 2), among which the clinical
measure of HDL-C was not associated with genetic variation only at
GCKR (2p23.3), as was also found in the fasting subsample (Figure 2,
Table 6). The discordant effects on LDL size and cholesterol content
at LPL (8p21.3), CCDC92/DNAH10/ZNF664 (12q24.31.B), and
LIPG (18q21.1) but not those of HDL size and cholesterol content
were independent of triglyceride level in as much as associations
persisted in analysis that further adjusted the lipoprotein fractions for
(log-transformed) triglycerides, although only at nominal significance
rather than genome-wide significance (Table 6).
By the same standards, loci could be identified with effects on
mean particle size but not total particle concentration (Table 6).
Thus, SNPs at LIPC (15q22.1) and LIPG (18q21.1) had genome-
wide significant associations for mean LDL particle size, but were
null for particle concentration in model selection procedures in both
the whole sample and the fasting subsample. These loci are
characterized by genes known to influence triglyceride metabolism.
Similarly, for HDL, comparison of associations with mean par-
ticle size and total particle concentration identified variation at
KLF14 (7q32.2), FADS1-3 (11q12.2), CCDC92/DNAH10/ZNF664
(12q24.31.B) and LIPC (15q22.1), implicating roles for known lipid
candidate genes as well as loci with unknown functions. Variation at
the novel locus WIPI1 (17q24.2), while not affecting mean HDL
particle size, was associated with the concentration of medium-sized
HDL, but not large or small HDL, total HDL particle concentra-
tion, or HDL-C (Table 2, Figure 2, Figure S4). In addition,
associations at LPL (8p21.3) in the fasting subsample distinguished
total HDL particle concentration from HDL-C (Table 6). VLDL
particle size but not concentration was influenced by variation at
8p23.1 in the fasting subsample but there were no genome-wide
significant associations at this locus in the whole sample. Again, in
triglyceride-adjusted analysis, discordant effects on mean particle
size and total concentration persisted but at some of the candidate
loci in the analysis of LDL and HDL (Table 6).
Lipoprotein candidate loci from other genome-wide
association studies
Recent genome-wide meta-analysis of lipoprotein LDL-C, HDL-
C, and triglycerides identified and validated 17 loci that were not
found at the genome-wide significance level in the current
population [10–12] in spite of comparable statistical power. We
examined SNPs within 100kb of each of these additional candidate
loci to extend associations to each of the NMR-based lipoprotein
fractions. The choice of a threshold p-value for significance is a
controversial issue in these analyses: although all of the candidate
loci had been validated previously, the current analysis was
performed in the context of a genome-wide association study. We
present all locus associations when statistical significance of
Bonferroni corrected p-value for the most significant locus
association was less than 0.05, accounting for the product of the
number of lipoprotein fractions tested (22) and the number of locus
SNPs considered (range 8–125) (Table S9 and Table S10). Seven
loci (TMEM57, GALNT2, TIMD4/HAVCR1, MADD/FOLH1/
NR1H3, MVK/MMAB, LCAT, CLIP2/PBX4/NCAN/SF4) met this
criterion in the whole WGHS sample and, at the same standard,
one more locus (MAFB) could be added in the fasting subsample.
Among these loci, associations with lipoprotein size measures were
found for LDL at GALNT2, and for HDL at GALNT2, MADD/
FOLH1/NR1H3, MVK/MMAB, CLIP2/PBX4/NCAN/SF4. No
associations at the stringent significance level were found with
mean VLDL size or total IDL concentration. Associations with
HDL and LDL total particle concentration were largely consistent
with parallel associations with ApoA1 and ApoB respectively.
Discussion
By performing genome-wide association analysis among 17,296
Women with European ancestry for 22 NMR-based and conven-
tional lipoprotein fractions, we identified 36 loci in the primary and
Table 6. Loci with genome-wide significant association
(P,5.061028) for mean particle size but no associations in
model selection procedures with cholesterol content or
particle number*.
locus Fraction‘
LDL mean size v. LDL-C LDL:T
7q11.23 (MLXIPL) W
8p21.3 (LPL) w/f
12q24.31.B w
15q22.1 (LIPC) w/f
18q21.1 (LIPG) w/f w/f
HDL mean size v. HDL-C HDL:T
2p23.3 (GCKR) w/f
7q32.2 w
8p21.3 (LPL) f
11q12.2 (FADS1-3) w/f
12q24.31.B w
15q22.1 (LIPC) w/f
VLDL mean size v. VLDL:T
8p23.1 F
*See Figure S4 for effects of individual SNPs across lipoprotein measures.
‘Bold typeface indicates differential associations for triglyceride adjusted
fractions with at least nominal significance. w =whole sampe, f = fasting
subsample.
doi:10.1371/journal.pgen.1000730.t006
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secondary analyses for roles in lipoprotein metabolism, broadly
defined. Ten of these loci have not been reported in other recent
genome-wide association studies, including one identified only after
adjustment for triglyceride levels. The functional bases for the
associations are uncertain for five, including associations at 8p32.1
and 12q23.2 that map to intergenic regions. In spite of the high
degree of correlation among some of the NMR-based and
conventional measures, two of the novel loci (PCCB [3q22.3] and
PPP1R3B [8p23.1]) could not have been found at the genome-wide
significance standard solely with conventional measures (or their
NMR-based equivalents) of lipoprotein profile in the WGHS.
Replication in independent cohorts of men and women as well as
other observations provided confirmatory evidence for candidate
variation at all novel, although only through internal replication at
SBF2 (11p15.4), CCDC92/DNAH10/ZNF664 (12q24.31.B), and
WIPI1 (17q24.2). The failure of external replication to validate these
two novel loci may simply reflect intrinsic differences from the
WGHS in NMR-based assay protocols (FHS) or clinical features of
the cohort (e.g. lipid lowering treatment in PROCARDIS) as well as
limiting power; alternatively, the associations observed in the
WGHSmay not reflect true genetic effects. Among the primary loci,
total genetic effects were largest and appreciable for ApoB, total
LDL, and others. They were the smallest for mean VLDL size.
While the heritability for the NMR-based fractions has not been
thoroughly explored, the present analysis suggests some aspects of
lipoprotein profiles may be much less affected by common genetic
variation than others. Combining the 31 loci in the primary
analysis, the five loci in the secondary analysis (three novel loci plus
APOH and LCAT), and the seven previously recognized loci for
which the WGHS extends associations to the NMR-based
lipoprotein measures brings the total to 43 loci characterized by
the present study.
As important as the total number of candidate loci, some loci
harbored variation exclusively correlated with the size of lipoprotein
particles rather their cholesterol or total concentration (Table 6). A
priori, one might have argued that triglyceride metabolic processes
would be critical in this respect. This notion was confirmed by
several candidate genes with known function in triglyceride
metabolism, for example the enzymes encoded by LPL, LIPC,
LIPG, and GCKR as well as the transcriptional regulatory protein
encodedMLXIPL all have activities that may alter equilibrium pools
of triglycerides and hence particle size or concentration. Other loci
with only partly understood function were also identified, and these
loci may now be further characterized through the current analysis.
While it remains possible that the loci in Table 6 contain genetic
variants not evaluated in this study and yet associated with
cholesterol content or total particle concentration, the discordant
effects on particle size compared with cholesterol or total particle
concentration suggest biochemical pathways impinging on aspects
of lipoprotein metabolism that are overlooked by standard clinical
testing. To the extent that the pathophysiology of cardiovascular
disease and related metabolic disorders, e.g. diabetes, is influenced
by the distribution of lipoprotein particle size there may be
therapeutic opportunities targeting the biochemical pathways
identified by the discordant associations.
The procedures in the primary analysis enforced a genome-wide
significance standard of P,561028 for each lipoprotein measure.
This standard was likely adequate for performing separate tests in
the whole sample and the fasting subsample (see Materials and
Methods) but does not explicitly address the multiplicity of testing
the 22 lipoprotein measures at once. In part, the burden of
significance is attenuated by correlations between the lipoprotein
measures (Table S2), but the correlations are not exact and
independent aspects of eachmeasure are revealed by the diversity of
effects shown in Figure 2 as well as by the discordant associations of
Table 6. However, the choice of P,561028 for genome-wide
significance can be further justified by false discovery rate (FDR)
analysis. For p-values from all of the lipoprotein measures
considered at once, the conventional standard requiring
FDR,0.05 implied a P,261025, more than two order of
magnitude less significant than the genome-wide p-value threshold.
Similarly, among the individual lipoprotein measures, FDR,0.05
implied at worst P,761027 for the case of IDL, still less significant
than our genome-wide standard by over an order of magnitude.
Thus, on a post-hoc basis, applying the conventional genome-wide
standard P,561028 for all fractions appears to have been justified.
Four of the 10 novel loci (7 from primary analysis, 3 from
secondary analysis) have functional links to lipoprotein metabolism
or disease status, even if strict biochemical roles of the candidate
genes and protein are not yet known. Variation at BTNL2
(6p21.32) has been associated with Grave’s disease, multiple
sclerosis, and sarcoidosis, apparently independent of the neigh-
boring HLA class DR genes [22–24]. In addition, the lipoprotein
association at this locus is within 780kb of a recently reported
association of rs2254387 with LDL-C attributed to the B3GALT4
gene encoding a galactosyltransferase [6]. At STAG1/PCCB
(3q22.3), the genome-wide significant association with small
HDL particle concentration is in the STAG1 gene, but a more
likely candidate for lipid metabolism may be the adjacent PCCB
gene encoding the propionyl coenzyme A carboxylase beta
subunit, in which substitutions cause Mendelian forms of
proprionic acidemia (see, for example [25]). At 8p23.1, over
150kb from the candidate SNP rs983309, PPP1R3B encodes a
phosphatase regulating glycogen phosphorylase, a plausible
regulator of glucose and triglycerides. At 17q24.3, the connection
to lipid metabolism can be made through an encoded domain of
WIPI1 protein, the WD40 domain, which is a structural motif
thought to interact with phospholipids [26]. The strongest
association at this locus is over 2Mb away but statistically
independent from the associations of rs1801689 with full-plus-
triglyceride-adjusted total LDL particle concentration or
rs2909207 with age-adjusted medium HDL particles (Table 5),
both adjacent to the lipid candidate gene APOH [27]. The
remaining six loci have intergenic status, or are proximal to genes
with unresolved connections to lipoprotein metabolism.
Nevertheless, association at one of these six loci, 12q23.2,
between rs7307277 and HDL-C measured by NMR involves the
same SNP we previously reported for genome-wide significant
association with plasma C-Reactive Protein (CRP) in a subset of the
current population [21], an association that remains highly
significant in the current sample (P=4.5610215). Previous reports,
including our own, had also identified associations at GCKR, APOC-
APOE complex, andHNF1Awith both lipid fractions and CRP [21].
We could now also add HNF4A to this list since rs4810479 at
20q13.12.A is associated in the WGHS with both CRP and the
lipoprotein fractions (Table 2, Table S1). These links between
lipoprotein metabolism and CRP are particularly intriguing given
the efficacy of lipid lowering therapy with statins among individuals
identified as at risk on the basis of elevated CRP [28].
The etiology of cardiovascular disease is complex, and is
believed to include an interplay between cell-based processes,
including inflammation, and blood components, including lipo-
protein fractions. The latter aspect may be summarized by clinical
measures of cholesterol or triglycerides, or by ApoA1 and ApoB
concentration. However, none of these aggregate measures reflects
the full diversity of lipoprotein species in blood. The current
investigation not only identifies novel loci for lipid metabolism in
general, but may also help delineate the impact of lipoprotein
Large-Scale GWAS of 22 Lipoprotein Measures
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metabolic genes on lipoprotein profile viewed with the highest
resolution currently available.
Materials and Methods
Ethics statement
All analyses were performed with approval of local institutional
review boards (IRBs).
Study populations
All samples in the discovery analysis derive from the Women’s
Genome Health Study (WGHS), a prospective cohort of North
American women with phenotypes related to cardiovascular
disease, extensive clinical and demographic data, blood samples
at baseline, and ongoing genome-wide genotyping [29]. The
current data derive from 17,296 WGHS participants with
confirmed, self-reported European ancestry who were non-
diabetic, not using lipid lowering therapy at baseline, and for
whom genotype information was available. Within this group,
12,489 (72%) provided the baseline blood sample at least 8 hours
after a meal and these participants constitute the fasting
subsample. Samples in the replication analysis derive from
PROCARDIS, an ongoing European study of premature
coronary artery disease [30,31], and from the Framingham Heart
Study (FHS) [32], an ongoing, family-based longitudinal cohort
designed to identify correlates with cardiovascular health,
including subgroup analysis of the impact of plasma lipoprotein
fractions. The FHS samples with NMR-based lipoprotein
measurements for replication derive from the Offspring cohort
within the FHS [19].
Lipoprotein determinations
In the WGHS, lipoprotein determinations were performed on
baseline plasma samples that had been stored in liquid nitrogen
(2170uC) since collection. LDL-C, HDL-C, triglycerides, ApoA1,
and ApoB100 levels were all measured by direct assay and had low
coefficients of variation [29]. NMR-based lipoprotein fractions
were determined as described by proton NMR spectroscopy
(LipoProtein-II assay, Liposcience Inc., Raleigh, NC) [33]. The
coefficients of variation for these measures were also low (range
0.4–7.1%), except for the concentration of medium HDL particles
(CV,30%) and IDL particle concentration (CV=13.1%) [4].
PROCARDIS measurements were also performed with LipoPro-
tein-II assays. Lipoprotein fractions for the FHS [19] samples were
measured with the LipoProtein-I assay (Liposcience Inc. Raleigh,
NC), which provides less accuracy for some measurements but is
otherwise similar to LipoProtein-II.
Genotyping
Genotyping in the WGHS sample was performed using the
HumanHap300 Duo ‘‘+’’ chips or the combination of the
HumanHuman300 Duo and iSelect chips (Illumina, San Diego,
CA) with the Infinium II protocol. In either case, the custom SNP
content was the same; these custom SNPs were chosen without
regard to minor allele frequency (MAF) to saturate candidate
genes for cardiovascular disease as well as to increase coverage of
SNPs with known or suspected biological function, e.g. disease
association, non-synonymous changes, substitutions at splice sites,
etc. For quality control, all samples were required to have
successful genotyping using the BeadStudio v. 3.3 software
(Illumina, San Diego, CA) for at least 98% of the SNPs. In the
final dataset, SNPs were retained with MAF .1%, successful
genotyping in 90% of the subjects, and deviations from Hardy-
Weinberg equilibrium not exceeding P=1026 in significance. A
total of 335,603 unique SNPs, of which 32,521 derive from the
custom content, remained in the final data. Although assays for
two non-synonymous SNPs at the APOE locus (19q13.32),
rs429358 and rs7412, which determine ApoE isotype, failed in
the design of the Illumina custom content, genotypes for these two
SNPs were determined separately by an allele-specific, PCR based
method (Celera, Alameda, CA) [34]. These additional SNPs are in
linkage disequilibrium with SNPs in the Illumina panel. The
targeted genotypes for APOE were included during the model
selection procedures but not during the primary analysis to
discover loci with genome-wide significant associations.
Analytic methods
Primary analysis to discover loci with highly significant
associations in the WGHS discovery cohort was performed by
linear regression in PLINK [35] assuming an additive relationship
between the number of copies of the minor allele of each SNP and
the mean values of the adjusted lipoprotein measures. A
conservative threshold of P,561028 was assumed for genome-
wide significance [36]. For each lipoprotein measure, a full
adjustment was performed by linear regression using the clinical
covariates: age at baseline (continuous), BMI (continuous),
menopausal status (yes/no), current smoking status (yes/no), and
use of hormone replacement therapy (yes/no). Concentrations of
IDL particles, total LDL particles, medium HDL particles,
triglycerides determined by NMR, and triglycerides determined
by chemical assay were log-transformed before adjustment to
approximate normality. Self-reported European ancestry was
confirmed among the WGHS participants included in the primary
analysis by clustering in a principal component analysis in PLINK
with 1443 ancestry informative SNPs chosen for large Fst values
(.0.4) among the HapMap CEU, YRI, and JPN+CHB
populations [37]. Discrepancy between self reported European
ancestry and the clustering pattern was observed only for 68
samples (,0.5%), and these samples were excluded from the
analysis. In addition, genomic control parameters for the primary
analysis were close to unity, ranging from 1.013–1.061. There was
an estimated 80% power at the genome-wide significance level to
detect effects explaining 0.23% and 0.32% of the variance in the
adjusted lipoprotein measures respectively in the whole sample
and the fasting subsample.
The primary analysis also included association testing in a
nested subset of 72% of the study participants who reported fasting
for at least eight hours before providing the baseline blood sample.
Analysis in this subset was expected to differ from the analysis in
the whole sample by opposing trends: a loss of power due to
reduced sample size was contrasted with possibly smaller variance
among lipoprotein fractions that are influenced by prandial status,
e.g. triglycerides. Because the majority of the sample was fasting,
the association statistics in the two samples were expected to be
highly correlated, and the statistical penalty for this additional
testing in the Bonferroni framework was expected to be less than a
factor of two. Our genome-wide significance threshold
(P,561028) was already smaller than required by correction for
the number of SNPs tested by a factor of three, and justified
including testing the fasting subset in the primary analysis.
Once loci having at least one genome-wide significant
association with at least one lipoprotein fraction had been
identified, a non-redundant set of SNPs contributing to each
lipoprotein fraction at each locus was constructed by forward-
backward stepwise selection using the Bayesian Information
Criterion (BIC) from among all genotyped locus SNPs within
100 kb of the locus genome-wide SNP associations. Separately,
these model selection procedures were performed also at each of
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the candidate loci with the unadjusted, but possibly log-
transformed, lipoprotein fractions to estimate the proportion of
variance explained without adjustment.
To assess the degree to which the adjustment procedure or sub-
European population stratification might influence the identifica-
tion of genome-wide loci, we performed a secondary analysis to
evaluate the sensitivity of the locus discovery procedure to the
adjustments applied to lipoprotein fractions before association
testing. First, we adjusted for all of the clinical covariates as well as
ten eigenvectors corresponding to a principal component analysis
of genotype frequency in EIGENSTRAT [38] among 64,208
SNPs chosen with inter-SNP LD r2,0.2 and followed by quantile
normalization of the residuals. Second, we adjusted with all of the
clinical covariates except BMI, either with or without inclusion of
the eigenvectors and subsequent quantile normalization. Finally,
we adjusted only for baseline age, again either with or without
inclusion of the eigenvectors and subsequent quantile normaliza-
tion. In an additional secondary analysis, the genome-wide
association procedures were performed with lipoprotein fractions
transformed and fully adjusted as for the primary analysis,
including also log transformed triglyceride levels among the
adjustment variables (see text).
Additional analytic procedures, including the hierarchical
clustering of loci according to effects on lipoprotein fractions, as
well as the graphical representations were programmed in R [39],
and included the False Discovery Rate analysis with the R-package
QVALUE [40]. All annotations derive from human genome
reference sequence hg18 (NCBI build 36.1), the UCSC Refseq as
of October 27, 2008, and the dbSNP database (build 129) as
represented by the UCSC database.
Analysis in replication cohorts
In the Framingham Heart Study (FHS) sample, residual
lipoprotein fractions were created by adjusting for gender, age at
exam lipoprotein fraction collection (continuous), age-squared
(continuous), and the top ten principal components from
EIGENSTRAT [38] before analysis. When appropriate, log
transformations were applied to approximate normality before
computing residuals. Association testing was performed in R [39]
using a linear mixed effect regression model with a kinship matrix
to account for the family structure in the sample. Genotype data
were derived by imputation using MACH 1.0 (http://www.sph.
umich.edu/csg/abecasis/mach/) from raw genotypes collected
with the Affymetrix (Santa Clara, CA) 500K array, and the
regression models assumed a linear relationship between the
dosage of the minor allele (ranging from 0 to 2) and the lipoprotein
measures [10]. Only SNPs with high quality imputation measures
(squared correlation of imputed and true genotype .0.3) were
used in the analysis. In the PROCARDIS study [20], where
genotype data derive from the Illumina (San Diego, CA) Human
1M platform representing a superset of the SNPs in the WGHS
data, lipoprotein fractions were adjusted for case/control specific
effects of age at baseline (continuous), gender, country of
recruitment (Germany, Italy, Sweden, United Kingdom), self-
reported hypertension (yes/no), diabetes (yes/no), current smoking
status by questionnaire (yes/no), and statin therapy (yes/no).
Regression models assumed a linear relationship between the
number of copies of the minor allele and adjusted mean
lipoprotein measure.
Supporting Information
Figure S1 Locus p-values for lipoprotein fractions with at least
one SNP reaching genomewide significance at each of the
candidate loci. All plots correspond to analysis in the whole
sample except for locus 8p23.1, for which genomewide association
was observed only in the fasting subsample as shown.
Found at: doi:10.1371/journal.pgen.1000730.s001 (0.41 MB PDF)
Figure S2 Primary loci clustered hierarchically according to
Cartesian distance corresponding to whether ( = 1) or not ( = 0)
there were associations with each of the lipoprotein fractions in the
model selection procedures (see Materials and Methods).
Found at: doi:10.1371/journal.pgen.1000730.s002 (0.02 MB PDF)
Figure S3 Dendorgram showing bierarchical relationships
between loci clustered as in Figure S2.
Found at: doi:10.1371/journal.pgen.1000730.s003 (0.01 MB PDF)
Figure S4 Normalized SNP effects (beta coefficients) from
univariate regression models. All plots correspond to analysis in
the whole sample except for locus 8p23.1, for which genome-wide
association was detected only in the fasting subsample as shown.
Locus SNPs are shown if they were retained in the model selection
procedure for at least one lipoprotein fraction. Absence of shading
indicates the univariate beta coefficient was not significant
(p.0.05). A small black dot for some combinations of SNPs and
lipoprotein fractions indicates genomewide significance for the
univariate beta coefficient.
Found at: doi:10.1371/journal.pgen.1000730.s004 (0.10 MB PDF)
Table S1 Best genome-wide associations with the lipoprotein
fractions at each candidate locus.
Found at: doi:10.1371/journal.pgen.1000730.s005 (1.10 MB
DOC)
Table S2 Correlations between all pairs of lipoprotein fractions.
Found at: doi:10.1371/journal.pgen.1000730.s006 (0.12 MB
DOC)
Table S3 Replication of WGHS candidate associations from
whole sample in PROCARDIS and the Framingham Heart
Study.
Found at: doi:10.1371/journal.pgen.1000730.s007 (0.56 MB
DOC)
Table S4 Replication of WGHS candidate associations from
fasting sub-sample in PROCARDIS and the Framingham Heart
Study.
Found at: doi:10.1371/journal.pgen.1000730.s008 (0.45 MB
DOC)
Table S5 Proportion of variance in fully adjusted lipoprotein
fractions explained in the whole sample by genetic variation at the
candidate loci.
Found at: doi:10.1371/journal.pgen.1000730.s009 (0.15 MB
DOC)
Table S6 Proportion of variance in fully adjusted lipoprotein
fractions explained in the fasting sub-sample by genetic variation
at the candidate loci.
Found at: doi:10.1371/journal.pgen.1000730.s010 (0.15 MB
DOC)
Table S7 Total proportion of variance explained by candidate
loci for each of the unadjusted lipoprotein fractions.
Found at: doi:10.1371/journal.pgen.1000730.s011 (0.04 MB
DOC)
Table S8 Sensitivity analysis for locus discovery procedure.
Found at: doi:10.1371/journal.pgen.1000730.s012 (0.10 MB
DOC)
Table S9 Lipoprotein associations in the whole sample at loci in
previous lipid fraction GWAS.
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Found at: doi:10.1371/journal.pgen.1000730.s013 (0.34 MB
DOC)
Table S10 Lipoprotein associations in the fasting sub-sample at
loci in previous lipid fraction GWAS.
Found at: doi:10.1371/journal.pgen.1000730.s014 (0.16 MB
DOC)
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